spacer
home > pmps > autumn 2017 > convenience, compliance and cartons
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Convenience, Compliance and Cartons

PMPS: Patient adherence is a current hot topic. Why is it of such interest to the industry?

Dr Daniel Keesman: Pharmaceutical companies lose hundreds of billions of dollars every year due to the fact that patients do not stick to their medication plan or do not take the prescribed medicine. Not only do they want to prove that their drugs are effective, pharma companies have an interest in improving adherence and compliance.

In your experience, what have been the biggest obstacles to adherence in pharma packaging over the past 10 years?

Primary packaging has improved in recent years, for instance, by inventing auto injection devices and pens to prevent the patient from seeing the scary needle. Secondary packaging is, unfortunately, very often thrown away, as it only serves as a transportation and value protection. Further, the leaflets are not put into the folding carton again after first use as nobody is able to fold them back to the same size it was when delivered.

Technical devices supporting adherence that could be attached to the packaging – such as displays or near-field communication chips that can be connected to smartphones – only make sense when the drug itself is worth having a packaging that costs 5-20 times more than without such a device.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Daniel Keesman, son of a German mother and a Dutch father, was born in New York, US, and is therefore still an American. For nearly 10 years, he has been part of the executive board of the quality-oriented pharmaceutical packaging manufacturer. He entered August Faller Group as Managing Partner in 2009 and is responsible for the development of national and international markets.
spacer
Dr Daniel Keesman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
More info >>

White Papers

Investigator Portals: Facilitating and Streamlining Communication & Collaboration with Study Sites

ArisGlobal

ArisGlobal LLC Investigator site personnel are often frustrated with the lack of transparency and communication with their sponsors, leading to significant dissatisfaction and withdrawal from current and future studies. The adoption of investigator portals gives sponsors a platform that fosters collaboration and improves site management. Learn about five key areas of sponsor-investigator site interactions deserving of electronic communication and collaboration. Technology and design aspects are also covered.
More info >>

 
Industry Events

5th Biennial Biosimilars & Biobetters Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global are proud to present our highly anticipated 5thBiennial Biosimilars & Biobetters Congress, 16th – 17thApril 2018, London, UK. Over 450 proteins, peptides and biosimilars delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions will enjoy over 20 presentations and case studies focusing on the key areas of the biosimilars industry including market access strategies, clinical development, commercialisation, manufacturing and bio-analytics
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement